The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) and is used in the treatment of seizures.
Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis
Rocuronium Bromide Injection had estimated annual sales of USD 54 million in the US (IQVIA MAT August 2023).
This product will be manufactured at Lupin’s Pithampur facility in India
This project will aim to develop a next-generation A3 adenosine receptor drug agonists
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
The vaccine further advances Pfizer’s vaccine portfolio and builds on more than 20 years of expertise and knowledge in the prevention of meningococcal disease
Lupin enters into BTA with Lupin Manufacturing Solutions
Subscribe To Our Newsletter & Stay Updated
